James' World 2

Click the link below the picture

.

The U.S. is finally getting a new, better sunscreen ingredient. Today, the Food and Drug Administration added bemotrizinol, an effective chemical filter that’s been used in sunscreens made in Asia and Europe for decades, to its list of permitted active ingredients in over-the-counter sunscreens. This list hasn’t seen a new entry in more than 20 years.

Bemotrizinol, also called BEMT, brings the list of approved active sunscreen ingredients in the U.S. to 17—a number that still lags behind Europe, which has more than 30 approved filters. While the FDA’s official action comes just seven months after the agency initially proposed it, critics have pointed out that the lengthy regulatory process prolonged bemotrizinol’s approval; the application was filed in 2005. The Environmental Working Group, an environmental health advocacy organization, has claimed this delay has caused U.S. sunscreens to fall behind in better coverage against harmful ultraviolet (UV) rays. Experts say today’s decision is a move in the right direction, offering people stronger protection from the sun.

Expanding sunscreen ingredient options in the U.S. is “a pretty big deal,” says AJ Addae, a chemist and doctoral candidate a University of California, Los Angeles, who studies cosmetics and sunscreen formulations. “It’s definitely something that we haven’t had in a very long time.”

How Bemotrizinol Works

There are two main classes of sunscreen filters: inorganic, or “physical,” and organic, or “chemical.” Sunscreens with physical filters—such as titanium and zinc—are mineral-based and are known to leave a white cast on skin. Chemical filters, such as avobenzone, octocrylene, and homosalate, appear clear when rubbed on the skin but sometimes feel oily. There are more organic filters than inorganic ones, but there aren’t as many approved ones in the U.S. as in other parts of the world, Addae says.

Contrary to popular belief, both types primarily work by absorbing UV light and converting that radiation energy into heat that is released from the skin, explains Saranya Wyles, a dermatologist at the Mayo Clinic in Minnesota. All sunscreens have the ability to reflect some light, though inorganic filters can reflect a little more, Addae adds.

UV radiation comes in two types: UVA and UVB. UVB is high-energy radiation that is typically associated with sunburns and can cause genetic mutations that lead to skin cancer, but UVA rays have increasingly become recognized as relevant for skin health, too. UVA is a longer-wavelength radiation that can penetrate deeper into the skin than UVB, breaking down the skin’s structure and creating harmful, skin‑aging molecules.

In the U.S., “the only thing that is really tested is a sunscreen’s ability to absorb UV light—specifically UVB light,” Addae says. This is how sun protection factor (SPF) is determined, but the measurement doesn’t capture UVA light. U.S. sunscreens offer only 24 percent of the protection indicated on SPF labels against UVA radiation, according to an analysis by the Environmental Working Group.

“When we think about a sunscreen, we want something to be broad spectrum,” Wyles says—meaning it covers both UVA and UVB. “What’s so exciting about this new BEMT filter is that it has more coverage in that UVA spectrum” compared with other organic filters. BEMT covers those “deeper UVA” rays that are often linked to photoaging of the skin, she says.

Safety and Stability Properties

Between various countries’ regulatory approval and real-world use, bemotrizinol has some of the most robust safety and efficacy testing among sunscreen filters. Following the ingredient’s development in the late 1990s by the now defunct Switzerland-based company Ciba Specialty Chemicals, the European Union adopted it into sunscreens in 2000. Canada and several countries in Asia followed suit soon after.

“A ton of safety data have had to be accrued in a lot of different populations,” Wyles says. Companies developing sunscreen filters need lots of funding to get the data needed for approval in the U.S., she adds.

Not only is bemotrizinol now the first filter to obtain the FDA’s stamp of approval since 1999, it’s also the first and only organic filter to receive the FDA’s safety and effectiveness standard, known as generally recognized as safe and effective (GRASE), for over-the-counter drugs or ingredients that don’t require full regulatory approval. The GRASE designation “is huge,” Addae says.

“I think that will kind of debunk the consumer’s perception that inorganic filters are generally recognized as safe and effective and organic filters tend to not be,” she says. “This shows that there can be organic filters that are that are determined GRASE.”

It’s impossible to draw “a clear line in the sand” on whether certain sunscreen ingredients are completely healthy for people or not, Addae says. But she adds that evidence has emerged that has given researchers some insight into how sunscreen filters generally interact with our bodies. Chemically, BEMT has larger chromophores—light-absorbing molecules—than other organic filters, which makes them less of a concern for adverse biological interactions, Addae says. In pharmacology and dermatology, researchers use the “500 dalton rule,” in which molecules with a molecular weight of more than 500 daltons are usually too large and bulky to pass through the skin.

“BEMT exceeds this limit quite well,” Addae says. “I think that’s likely a large reason why the GRASE status was on the table for this particular filter.”

Scientists are investigating whether BEMT degrades in pool water. It’s unclear if subsequent chemical by-products after a breakdown of BEMT might cause irritation or damage to the skin. In sunlight, though, most evidence suggests that BEMT is quite stable and longer-lasting than other filters. “BEMT is one that does stay on longer, but this doesn’t mean you can apply this and then you don’t have to reapply for a long time,” Wyles says. “That degradation curve varies for everybody.”

The FDA evaluated the safety and efficacy of BEMT concentrations of up to 6 percent and considered how BEMT interacts with other sunscreen filters and ingredients. Because companies will only be able to use up to 6 percent concentrations of BEMT in formulations, Wyles doesn’t anticipate it will fully replace existing U.S. filters.

“A lot of times, you’re not going to see BEMT standing alone; it’s going to be combined with other sunscreen filters,” Wyles says.

The Future of UV Filters

Researchers are keeping tabs on how BEMT’s approval will affect the approval of other UV filters in the U.S. Wyles says others in the BEMT family might see similar approvals. Another organic filter, Mexoryl 400, has also demonstrated coverage of the UVA spectrum and is increasingly found in sunscreens produced in Asia and Europe. “I can see that coming to the U.S. at some point,” Wyles says.

Addae, who also created a research-and-development lab to make products for cosmetic chains, recently worked with her colleagues at U.C.L.A. to create a mineral-based filter with less of a white cast. She changed the chemical properties of zinc oxide to reduce aggregation that causes a white cast. The filter scattered light differently but still absorbed UV rays effectively. It was more effective with UVB than UVA rays, however. Further efficacy testing is needed, but the filter wouldn’t require new regulatory approval, she says.

BEMT sunscreens are anticipated to hit U.S. shelves later this year. The Dutch company DSM Nutritional Products will be the first in the U.S. to sell its BEMT-formulated sunscreen, Parsol Shield, according to the Associated Press. The company has an 18-month exclusivity period, after which the other manufacturers can start using the ingredient. Addae adds that it will take some time for U.S. chemists and companies to incorporate the filter into new products and learn best practices.

“At the end of the day, what matters is that people wear their sunscreen, no matter what’s in it,” she says.

.

Pablo Jeffs Munizaga/Fototrekking/Getty Images

.

.

Click the link below for the complete article:

.

__________________________________________

Hmmmm … No Lamborghini for me! Can’t afford repairs!

Click the link below the picture

.

Owning a $4 million Lamborghini collection sounds like a dream – until reality kicks in. Behind the perfect looks, these cars are filled with problems, from oil leaks and misfires to failing clutches and electrical chaos. Years of putting off repairs have finally caught up, and now the cost to fix everything is overwhelming. What seems like luxury quickly turns into a constant battle just to keep them running. It’s a rare look at the truth behind owning some of the most desirable cars in the world.

.

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

After nearly four years, the World Cup is back to take over the summer. But alongside celebration for the sumptuous soccer to come, there’s ample cause for consternation. This year’s tournament, jointly hosted by the United States, Mexico, and Canada, will play out against a backdrop of endemic FIFA corruption, President Trump’s depredations, and severely strained relations between the host nations.

To gauge the mood on the eve of the competition, we asked three writers — an American, a Mexican, a Canadian — what the World Cup means to them and their countries. Their varied responses testify to both the maddening complexity of contemporary life and the enduring wonder of world soccer.

It’s Not U.S. 1994, but It’s Something

It’s not easy to explain, to kids growing up today surrounded by screens and viral videos, the epiphanic force with which the men’s World Cup landed on American TV in 1994. It certainly did on the old Magnavox TV in my parents’ house in northern New England’s woods. Like many American kids in the waning years of the Cold War, I spent my Saturday mornings kicking a ball around American fields. I had joined a travel team whose sponsor’s logo (“CABOT: Cheese from Vermont”) vied for space with Adidas on our chests. But I’d never seen the game played at the highest level — until 1994.

To live in range of ABC’s coverage of the games that summer was to glimpse the world’s finest players and best-loved teams. It was also to be treated to vivid and at times incongruous tableaux of ethnic fervor and comity, involving not merely those teams but their impassioned fans, too. They filled America’s biggest arenas — green-clad Nigerians and sombrero-wearing Mexicans, Swedes in Viking hats and Argentines singing songs about Diego Maradona. Feelings of national rivalry and pride occasioned not war but play.

To take in those games, as ABC’s commentators informed us, was to watch telecasts also being absorbed by billions of other humans — and to participate in the world.

In 2026, the world doesn’t look like we hoped it might from the sunny vantage of the early 1990s, when history still felt like it was moving in a positive direction. The United States, which seemed destined to be increasingly open-minded, is more closed off. But the return of the World Cup, a competition founded in the same era as the League of Nations and involving a sport that Americans have now learned to love, will still channel conflicts between countries into “peaceful contests in the stadium,” as Jules Rimet, the man who masterminded the competition, once put it. As important, it will offer us all a chance to experience, even if just for a moment, a mighty form of communion.

In 1994, the Cold War was over, and America — notwithstanding Washington’s frequently awful proxy wars in developing countries — was admired as the global paragon of democracy and the rule of law. But the sporting culture in the United States was insular and jingoistic. It was defined by sports that Americans evolved from the games of our colonial masters: Gridiron football was a more dynamic and violent form of English rugby; baseball was an American riff on cricket. Americans took pride in the fact that few others in the world cared about or played our “national pastime.”

Association Football — a game with ancient global roots but whose modern form was, like rugby and cricket, codified in England — became the globe’s game thanks to factors both of history and of form. The British Empire brought British sailors, engineers, and miners to the world’s ports. The game they played by wharves from Buenos Aires to Accra to Hong Kong was embraced by people who founded clubs in those cities and a thousand more. Soccer became the 20th century’s pre-eminent way for people around the world to hail, as the soccer historian David Goldblatt put it, “the miracle of our own solidarities.”

Except in the United States — until 1994, anyway. That summer’s World Cup was the best-attended and most-watched tournament that soccer’s worldwide governing body, FIFA, had ever staged. This was the goal. FIFA and its partners, among them some of the world’s biggest companies and media conglomerates, aimed to make the globe’s best-loved sport a big business in the world’s richest market.

In the 32 years since the 1994 World Cup, the dreams of FIFA and its corporate cronies have in large part come to pass. We follow the world’s top leagues on TV, and our women’s team are worldbeaters. Soccer, according to one recent poll, has surpassed baseball as Americans’ third-favorite sport. Among teens, it comes close to rivaling the N.B.A. for hearts and eyeballs.

Now the World Cup is back. Since 1994, the reputations of both the United States and FIFA have taken some profound dings. FIFA’s corruption was never exactly a secret, but has now been exposed to the world. President Trump’s contempt for the rule of law and international norms has done vast damage to America’s global standing and American society alike.

The reason FIFA’s flagship event has returned to the world’s richest country, this time sharing hosting duties with our North American neighbors and cosignatories to NAFTA that Mr. Trump loves to hate, is the same reason that Gianni Infantino, FIFA’s unctuous current head, expanded this World Cup from 32 nations to 48: cash.

.

World Cup

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

On Tuesday, NASA revealed the four astronauts who will crew its upcoming Artemis III mission—the agency’s critical next step toward landing humans back on the moon for the first time in more than 50 years.

The four astronauts who will fly on the mission, currently slated for 2027, are NASA astronauts Andre Douglas, Frank Rubio, and Randy Bresnik and European Space Agency astronaut Luca Parmitano.

Douglas is a spaceflight rookie who will serve as mission specialist alongside Rubio, who holds the record for the American with the longest spaceflight. Parmitano will be Artemis III’s pilot, and Bresnik will be mission commander. Should any of the four need to pull out of the mission, there is a back-up crew member: NASA astronaut Bob Hines.

According to NASA’s official timeline, Artemis III could launch as early as the second half of 2027, but many experts expect that schedule to slip. Originally conceived as the first U.S. crewed moon landing since 1972’s Apollo 17, NASA overhauled the mission’s scope earlier this year to make it a test flight in low-Earth orbit. There, the four astronauts will seek to rendezvous NASA’s Orion crew capsule with two separate Human Landing System (HLS) vehicles. In future Artemis missions, such HLS spacecraft will ferry crews from lunar orbit to the surface of the moon and back.

“Artemis III is an incredibly exciting, complicated, and highly coordinated multilaunch campaign. It’s going to happen in a short period of time with three of the world’s most powerful rockets,” said Jeremy Parsons, acting assistant deputy associate administrator for NASA’s Moon to Mars Program Office, at Tuesday’s announcement.

The mission will begin with the launch of Blue Origin’s lander test vehicle, which Parsons said can “loiter” in space for up to 90 days. The crew will launch inside the Orion capsule via the space agency’s Space Launch System rocket. Then they will orbit in a circular trajectory around Earth before they attempt to rendezvous the Orion capsule with the Blue Origin lander. The paired spacecraft will spend around two days together, enabling technology demonstrations and tests—including inside the Blue Origin spacecraft, Parsons said.

After that, the Orion capsule will detach from the Blue Origin spacecraft and perform a similar meetup and demonstration with a version of SpaceX’s Starship.

“This gives our teams key information on systems the lunar lander crew will depend on an environment close to home versus four plus days away around the moon,” Parsons said. “This mission is deliberately designed to take calculated risks so that future crews will be safer and ultimately successful when we put boots on the lunar surface.”

During their mission, the crew will spend around two weeks inside their Orion capsule—about four days more than their predecessors did in April’s Artemis II mission, a nearly 10-day voyage that took four other astronauts looping around the moon’s farside.

Artemis III’s objectives also include a space walk and other tests of the agency’s latest space suits, which are being designed and made by the aerospace company Axiom Space and the fashion firm Prada. The basic outline is similar in sequence and scope to Apollo 9, a 1969 mission that was a critical precursor to Apollo 11, the first-ever human moon landing, later that year, and that was itself preceded by 1968’s moon-orbiting Apollo 8.

For now, NASA’s human return to the moon is planned for 2028 via the Artemis IV mission. At the Tuesday event, NASA chief Jared Isaacman said that Artemis III will be critical to getting into the rhythm necessary to make Artemis IV and future moon missions achievable.

The Artemis III crew “are carrying, carrying forward the hopes and dreams of the next generation, just as the Apollo astronauts did for so many of us,” Isaacman said. “When [astronaut] Gene Cernan left the lunar surface on Apollo 17, he said, ‘We leave as we came, and God willing, we shall return with peace and hope for all mankind.’ Now it’s taken a little bit longer than he may have imagined, but we are returning, and we do so with the experience of Apollo, the lessons of Artemis II, the crew, now, of Artemis III, and the promise of what lies ahead and our collective effort to build out humanity’s first outpost on another world.”

Both SpaceX and Blue Origin are vying to supply the HLS; SpaceX’s lander is a variant of its enormous Starship rocket, which has yet to fully reach Earth orbit despite a dozen test flights. Blue Origin’s HLS contribution is its in-development Blue Moon lander, which would lift off on the company’s huge New Glenn rocket. That latter plan, however, suffered a major setback after a New Glenn exploded—destroying some of Blue Origin’s mission-critical infrastructure—during testing on the company’s launchpad on May 28. The company’s CEO, David Limp, has vowed that New Glenn will return to flight before the end of this year—a sentiment echoed on Tuesday by John Couluris, Blue Origin’s senior vice president of lunar permanence.

Even if both companies manage to meet those ambitious deadlines in time for Artemis III, other hurdles remain. To actually get crews to the lunar surface and back, Starship and Blue Moon alike would require in-space refueling—a scarcely tested maneuver that carries significant risks and the possibility of further delays. At the same event on Tuesday, SpaceX’s vice president of customer operations and integration, Jessica Jensen, said the company will attempt a fuel transfer in space later this year. SpaceX CEO Elon Musk is targeting late 2026 for Starship’s next launch.

Artemis III won’t test refueling even under ideal circumstances, which suggests that capability will require further uncrewed test flights of both HLS systems before either one can be used for a crewed lunar return.

“Let me assure you, NASA is taking an active role with all of our partners, contractors, and vendors to help solve the problems that are here today and ensure the right outcomes are achieved,” Parsons said.

Jensen said SpaceX is planning to use a Starship V3 with a docking mod borrowed from its Crew Dragon capsule, which SpaceX uses to ferry NASA astronauts to the International Space Station, for Artemis III. The firm is also building a Starship HLS cabin at its Starbase site in Texas to further test its systems on Earth before a moon landing.

Isaacman said that NASA will release a further update on its moon base plans in the coming weeks.

.

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

Key Takeaways

.

Two young girls watch as Old Faithful is Erupting.

.

.

Click the link below for the complete article:

.

__________________________________________

Hmmmm … Sic Semper Tyrannis, Epstein, Epstein, Epstein, Epstein!

Click the link below the picture

.

A new kind of institutional vandalism appeared last month in the form of a 412-page Trump administration regulatory proposal and a comment period. If the proposal passes, it will damage one of the most rigorous, productive and valuable scientific enterprises in the world.

The Office of Management and Budget has called for a rule change that would impose restrictions on the kinds of research that can be funded and give political appointees the final authority to deny federal funding for research deemed inconsistent with presidential priorities. Such a revision is necessary, the agency said, because there is a “lack of transparency, accountability and proper oversight” in the way federal funds are dispersed. That led to the waste and misuse of federal funds to “promote a ‘woke’ policy agenda,” according to the agency, particularly the diversity, equity and inclusion programs of the Biden years.

O.M.B.’s solution is to weaken the very process that already ensures a strong degree of accountability: The proposal demotes peer review where expert scientists, working inside and outside the agencies, evaluate research based on the scientific merits and strengths of the underlying evidence. Instead of being “routinely deferred to,” peer review would now be only “advisory.” That upends the longstanding compact between the federal government and the scientific community, where Congress appropriates funds, agencies administer them and scientists (through peer review) determine which proposals represent the best science.

Right now, the political appointees who lead agencies such as the Department of Health Human Services have broad authority to administer their agencies’ programs and set new priorities. But they didn’t typically do political evaluations of scientific research proposals. The new rules expand their power over which grants get approved based on whether the projects align with political ideology. The incentive to prioritize loyalty to a political leader over quality and America’s needs would be strong.

Scientists are not infallible. This is why we have checks and balances — enforced by our peers — built into the grant review and publication process. From the outside, it may look inefficient, and it certainly is not perfect. But it’s the best, most transparent and externally verifiable process we have. The proposed rules would take us in a different direction, corrupting the conditions under which rigorous science operates for the public good.

Let’s say the administration doesn’t like the scientific justification for a grant proposal on climate change, vaccines or the health disparities that women of color experience. A political appointee would have the power to deny funding relating to these topics. Appointees could also terminate an active grant project if they decide it is politically or ideologically inconvenient. As written, the proposed rules would govern virtually every grant from every federal agency, including housing, disaster recovery, transportation and Medicaid. Such sweeping power would affect billions in grant funding paid for by taxpayers.

Who would benefit from the proposed rules? For one, politically connected industries — including those that may want to obscure scientific links between their products and harmful health effects. Other beneficiaries might include partisan think tanks, pseudoscientists or even government agencies that may shirk their legal obligations to protect the public.

Other knock-on effects would be profound. Scientists and graduate students would learn quickly which topics are unlikely to be approved. Entire fields could wither without funding not because the science is weak or unimportant, but because it is unwelcome. One day, American taxpayers might wake up and demand to know why we fund research on baseless conspiracy theories rather than investing in our collective future.

An alternative path to the proposed rules exists: the Scientific Integrity Act, a bill with bipartisan support that was reintroduced in the House in 2025. It would protect federal agencies and scientists from political interference by requiring that every federal agency that funds, conducts or oversees scientific research establish and maintain clear scientific integrity standards. It would also help ensure that policy decisions are based on independent, evidence-based science. If the bill were to become law, scientific integrity would become a robust and permanent requirement rather than something vulnerable to executive branch interference.

.

Chloe Niclas

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

CHICAGO—At the world’s largest oncology conference, Ozempic, a diabetes drug, found its way to the center of the conversation. As thousands of attendees bounced between presentations at the American Society of Clinical Oncology (ASCO) meeting, some of the biggest buzz focused on the connection between taking Ozempic and similar glucagonlike peptide 1 (GLP-1) receptor agonists and having a decreased risk of several types of cancer.

GLP-1 drugs, originally designed to treat type 2 diabetes, have become blockbuster treatments for weight loss and metabolic conditions such as heart, liver, and kidney disease. Now researchers are investigating whether certain cancers, such as breast cancer, could be added to that list. At the conference, scientists announced their findings that people taking GLP-1 drugs were less likely to be diagnosed with certain cancers, have them spread, or die from them when compared with nonusers and those on other diabetes medications. Even though the findings are largely based on observational studies, they reinforce animal research that shows GLP-1 drugs do more than just shed pounds and improve metabolic health. The drugs may also dial down the inflammation that can drive cancer development—and might even act directly on tumors.

Obesity has long been identified as a risk factor for at least 13 types of cancer. Excess weight promotes chronic inflammation, raises insulin levels in the blood, and increases estrogen circulating in the body—all potential drivers of cancer development. Whether GLP-1 treatments reduce cancer risk by reversing these pathways through weight loss, or through some other mechanism entirely, remains an open question. Several lines of research presented at ASCO offer evidence of the drugs’ protective effect against cancer, including several not typically associated with weight, such as leukemia and lung cancer, says Elizabeth McDonald, radiologist at the Hospital of the University of Pennsylvania.

McDonald’s team at the University of Pennsylvania found GLP-1 drugs were linked to a 30 percent lower likelihood of a breast cancer diagnosis in more than 111,000 women who underwent breast imaging. Another large analysis from the Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, published in JAMA Network Open before the conference, followed breast cancer patients for up to 10 years and found that those who took GLP-1s had a lower risk of death from any cause—and a reduced risk of cancer recurrence—compared with patients who did not take them. And in another investigation, co-led by researchers at Massey, found that GLP-1 drugs were associated with improved survival among people with colorectal cancer as well. A Cleveland Clinic study tracking people across seven cancer types found that those taking the drugs were significantly less likely to progress to stage four disease in lung, breast, colorectal, and liver cancers—with a 43 percent risk reduction seen in breast cancer and a 50 percent reduction in lung cancer.

These studies collectively provide an “interesting signal,” says Jasmine Sukumar, a breast medical oncologist at the University of Texas MD Anderson Cancer Center, who also presented research on GLP-1s’ protective effect against breast cancer. The data are still observational, which means the research teams cannot prove cause and effect, she adds. Still, Sukumar and other scientists are trying to understand what might be driving these findings.

The most straightforward explanation is the weight loss that the drugs can cause. Reducing weight also reduces the pathways by which obesity fuels cancer, explains Bernard Fuemmeler, associate director of population science at the VCU Massey Comprehensive Cancer Center and a co-author of the breast cancer study and the colorectal cancer study presented at ASCO. The drugs may also reduce deaths through their effect on cardiovascular disease, he says. Additionally, fat tissue is a source of estrogen, so shrinking fat tissue reduces the hormones that promote certain types of breast cancer tumors.

But some of the new research suggests a mechanism that goes beyond weight loss. GLP-1 drugs could be working on inflammation, which is a key driver linked to tumor development. Chronic inflammation can create conditions that help cancers take root and spread. Because GLP-1 receptors are found throughout the body, not just in the gut and pancreas, activating them appears to dampen inflammation through multiple pathways—such as by acting on immune cells and endothelial cells, and other vascular cells or by influencing body-wide inflammatory cascades that affect multiple organs.

GLP-1 drugs might also act on tumors directly. In animal studies, tirzepatide—the dual-receptor drug sold as Zepbound—appears to have target tumors in breast cancer and endometrial cancer, possibly by reversing the inflammatory effects of obesity and inhibiting tumor growth.

Certain cancers might be more responsive to GLP-1 treatment. For instance, the Cleveland Clinic researchers found that, across seven tumor types, people who had tumors packed with GLP-1 receptors were 33 percent less likely to die during the follow-up period; people with breast cancer tumors had the greatest improvements in survival. High amounts of such receptors in breast cancer tumors might explain the higher survival rate, but it’s not fully understood, says Mark Orland of the Cleveland Clinic Taussig Cancer Institute, who led the analysis.

“Each of these cancers has to be looked at fairly individually and very specifically, stage by stage and mutation by mutation,” Orland says.

He and his Cleveland Clinic colleague Jaroslaw Maciejewski, a co-author of the research, speculate that the drugs might also be working through something more systemic. Early-stage cancers can only progress in the right environment, one often shaped by aging-related chronic inflammation. “Such an effect would not necessarily be tumor-specific,” Maciejewski says. One possibility is that GLP-1 drugs might be narrowing the gap between chronological age and biological age, the apparent age of various tissues. This could mean GLP-1 drugs may affect biological aging more broadly, the researchers suggest.

Orland says that the field is still far from calling GLP-1 drugs the next big deal for cancer treatment. “It would be a little bit aggressive to say it’s going to cure my cancer or stop my cancer,” he says.

While there isn’t strong evidence to suggest that the drugs worsen cancer in humans, the Food and Drug Administration has warned against their use among people with a family history of certain thyroid cancers, with the agency citing rodent studies. Cancer patients and survivors would also need to carefully monitor their loss of muscle mass, a common side effect of the drugs, during any potential GLP-1-based cancer therapy, Fuemmeler says. For now, clinicians are holding off on prescribing GLP-1 drugs to prevent or treat cancer until there is more research, particularly human clinical trials, which some researchers are already beginning to design. “We don’t know for sure if these [initial] results will hold up in a randomized clinical trial,” Fuemmeler says. “All of these mechanisms are really ripe for future investigation.”

.

Alvaro Medina Jurado

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

Key Takeaways

• Research shows that college graduates could be haunted by a weak job market in the form of reduced earnings and employment opportunities.
• Unemployment for 22‑ to 27‑year‑old college grads is around 5.6 percent, noticeably higher than in recent years and unusually elevated relative to the broader workforce.
• More than 40% of employed recent graduates are working in jobs that do not require a college degree, the highest share since 2020.

Today’s class of college graduates is entering one of the weakest labor markets in years, and research suggests that those early setbacks could echo through their earnings and careers for at least a decade. 

According to a recent report from The New York Times, recent college graduates are stepping into the most challenging job market since the depths of the pandemic. An analysis from the Federal Reserve Bank of New York shows that unemployment among 22- to 27-year-old college graduates has increased over the past three years, reaching 5.6% in the first quarter of the year. 

That’s above the 4.2% overall jobless rate. College graduates usually enjoy lower unemployment than the broader workforce, so the current gap is a sign that entry-level hiring has weakened disproportionately. 

At the same time, underemployment has surged. More than 40% of employed recent graduates are in roles that do not typically require a college degree, the highest level since 2020, per the Federal Reserve Bank of New York. 

“The overall labor market is not in a recession right now,” Larry Katz, a labor economist at Harvard, told the Times. “But it’s clearly feeling like a recession for young college graduates entering the labor market.”

Economists told the Times that the tough job market means graduates are likely to earn less and face more challenges in advancing their careers. Research has repeatedly found that the year a worker leaves college, and the state of the economy at that moment, can shape how much they earn in the long term.

One study examined the effects of a weak job market on wages 

One influential study by Lisa Kahn, an economist at the University of Rochester, examined what happened to students who graduated around the deep recession of the early 1980s, following them for many years before, during and after that downturn. 

She compared them to cohorts who were otherwise similar, but who entered the labor market under very different macroeconomic conditions, when the economy was a little better. 

Khan’s core finding was that graduating from college when unemployment is high and jobs are scarce has a clear, measurable and long-lasting negative impact on wages. 

New graduates who started their careers in that weak labor market accepted lower‑paying jobs than they likely would have in better times, and those smaller paychecks did not simply snap back when the economy recovered. Instead, their earnings grew from a lower base, so even as conditions improved, the initial penalty continued to linger.

Fifteen years after graduation, workers who entered the job market during the downturn were still earning less, on average, than similar peers who began their careers in healthier job markets. 

Now Kahn warns that the current group of college graduates could be haunted by a weak job market in the form of reduced earnings and employment opportunities. 

“There are going to be lasting effects,” Kahn told the Times. “The cohorts that were lucky enough to just finish a little bit earlier or a little bit later I think are going to be doing better.”

.

Young graduates are entering the toughest hiring climate since the pandemic

.

.

Click the link below for the complete article:

.

__________________________________________

Click the link below the picture

.

When Jeffrey Epstein wanted his favorite Zweigle’s Pop Open hot dogs ferried from his townhouse on the Upper East Side of Manhattan to his sprawling Zorro Ranch in New Mexico, he did what any exceedingly rich person might.

He had his staff reach out to a close friend with a private jet. Stephen Hanson, then head of a Manhattan restaurant empire that at its peak served more than 20,000 people a day at 25 theatrical, high-volume restaurants like Blue Water Grill, Dos Caminos, and Ruby Foo’s, was happy to make the delivery himself.

“In the white freezer in downstairs kitchen of 71st street, there are packages of frozen hot dogs,” Mr. Epstein’s private chef emailed an assistant. “JE would like to have hot dogs for lunch tmrw and these are the new dogs he likes.”

There was one other favor Mr. Epstein wanted on that August weekend in 2012. He asked Mr. Hanson to make room for a woman who would be bringing a wallet he’d left behind, according to documents the Department of Justice collected as it investigated Mr. Epstein. She was later paid settlements from funds established for Mr. Epstein’s victims.

The Justice Department files attest to Mr. Epstein’s transactional relationships with many powerful men. Billionaires like the Victoria’s Secret magnate Les Wexner and the private equity investor Leon Black helped build his fortune. Boldfaced names like Woody Allen and Andrew Mountbatten-Windsor, the former British prince, provided cachet and social access.

What Mr. Hanson offered, a review of the thousands of emails and texts the two men exchanged over a decade, shows was access to the world of food and hospitality — as well as a wingman who enjoyed the company of attractive women, and had the means to help manage and entertain them.

Mr. Hanson got the young women tables in his dining rooms. He arranged cooking classes for them. When Mr. Epstein asked him to help women land visas or find jobs in his restaurants, the answer was almost always yes.

During their long friendship, Mr. Hanson became one of the most powerful people in the restaurant business. In 2003, Bon Appétit magazine named him restaurateur of the year, and he expanded his reach to Las Vegas. By 2007, his company, BR Guest Hospitality, was valued at $300 million.

Mr. Hanson still found time, the files show, to aid his friend in all kinds of ways. He recruited people to manage Mr. Epstein’s private Caribbean island compound and set up tastings to help him hire the perfect private chef. No errand was too small. When the beef jerky that fueled one of Mr. Epstein’s odd dietary binges didn’t taste quite right, Mr. Hanson worked on the recipe. He even had his executive assistant send a sample to a laboratory to test its nutritional value.

Nothing in the files or other public records indicates that Mr. Hanson had sex with minors, as Mr. Epstein did. In a video interview in 2021, a victim of Mr. Epstein’s told the F.B.I. that a decade earlier, when she was in her early 20s, Mr. Epstein had sent the restaurateur to her New York City apartment, where Mr. Hanson paid her for oral sex at least a dozen times.

The woman, who first met Mr. Epstein when she was 17, said she had become dependent on Mr. Epstein and did whatever he requested. Her name was redacted in the files, and her lawyer, Gloria Allred, declined to comment. A Justice Department spokeswoman would not say whether the agency had investigated further, but Mr. Hanson has never been charged with a crime.

In response to questions for this article, Mr. Hanson did not address the woman’s allegations, but issued a brief statement through his lawyer, Gerald B. Lefcourt, a former attorney for Mr. Epstein. “Mr. Epstein knew and relied upon Mr. Hanson for advice on certain matters given Mr. Hanson’s hospitality industry experience,” it read in part. “Mr. Epstein was adept at deception and manipulation. He pulled the wool over the eyes of leading academics, scientists, and titans of business. The suggestion, assumption, or insinuation that there was anything untoward about, in relation to, or concerning, any connection between Mr. Hanson and Mr. Epstein is untrue.”

.

The bond between Stephen Hanson, left, and Jeffrey Epstein stretched over decades, a review of Department of Justice files shows. It included vacations like this 2013 trip to Las Vegas. Credit…U.S. Department of Justice

.

.

Click the link below for the complete article:

.

__________________________________________

.

.

“When a clown moves into a palace, he doesn’t become a king, the palace instead becomes a circus. — Turkish proverb,”

 

Hmmmmm…History is repeating itself yet again!

 

Isaiah 59:14

New Living Translation

.

__________________________________________